Synaptic plasticity dysfunction is a central pathological feature of Parkinson's disease (PD), contributing to both motor and non-motor symptoms. This page explores therapeutic technologies targeting synaptic plasticity enhancement, including mechanisms of action, clinical trials, and the developing pipeline of disease-modifying treatments.
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Synaptic Plasticity Enhancement |
| Diseases |
Parkinson's Disease, Parkinson-Plus Syndromes |
| Stage |
Preclinical to Phase II |
Synaptic loss and dysfunction in Parkinson's disease occurs early in disease progression and correlates strongly with clinical disability. Unlike dopaminergic therapies that provide symptomatic relief, synaptic plasticity-targeted approaches aim to preserve or restore synaptic function, potentially slowing or halting disease progression.
The progressive loss of dopaminergic neurons in the substantia nigra pars compacta leads to:
- Striatal synaptic remodeling: Loss of dopaminergic modulation of medium spiny neurons
- Cortical-striatal circuit dysfunction: Disrupted cortico-striatal connectivity
- Thalamic over-activation: Abnormal excitatory drive to motor cortex
- Network-level desynchronization: Disrupted beta-band oscillations
Key mechanisms include:
- Long-term potentiation (LTP) deficits: Impaired NMDA receptor-dependent synaptic strengthening
- Long-term depression (LTD) dysregulation: Abnormal synaptic weakening
- Dendritic spine loss: Reduced spine density in corticostriatal neurons
- Extrasynaptic receptor changes: Altered tonically active NMDA/AMPA receptors
NMDA receptors are critical for synaptic plasticity induction. In PD, NMDA receptor function is altered, contributing to plasticity deficits.
NMDA Receptor Partial Agonists
- Target: GluN2A/2B-containing NMDA receptors
- Mechanism: Sub-maximal activation to enhance plasticity without excitotoxicity
- Example: D-serine supplementation (co-agonist)
NMDA Receptor Modulators
- Target: Allosteric sites on NMDA receptors
- Mechanism: Enhance receptor trafficking and function
- Challenge: Balancing efficacy with side effects
NR2B-Selective Modulation
- Target: GluN2B subunit-containing receptors
- Mechanism: Enhance synaptic plasticity in striatal neurons
- Status: Preclinical validation ongoing
AMPA receptors mediate fast excitatory neurotransmission and are crucial for synaptic plasticity expression.
Positive Allosteric Modulators (PAMs)
- Target: Allosteric sites on AMPA receptors
- Mechanism: Enhance receptor function and promote LTP
- Example: CX516 (Ampakine)
AMPA Receptor Agonists
- Target: AMPA receptor agonists with favorable properties
- Mechanism: Direct activation to enhance synaptic transmission
- Challenge: Rapid desensitization
AMPA Receptor Trafficking Modulators
- Target: Proteins regulating receptor internalization/externalization
- Mechanism: Promote surface expression
- Example: Targeting PICK1, GRIP1
Dendritic spines are the primary sites of excitatory synapses. In PD, spine density decreases, contributing to synaptic dysfunction.
Small Molecule Enhancers
- Target: Proteins regulating spine formation and maintenance
- Mechanisms:
- Actin cytoskeleton modulators
- Rho GTPase pathway modifiers
- Synaptic scaffolding protein stabilizers
Growth Factor Signaling
- Target: BDNF/TrkB pathway
- Mechanism: Enhance neurotrophic support for spine maintenance
- Challenge: Blood-brain barrier penetration
Cell Adhesion Molecule Modulators
- Target: Synaptic cell adhesion molecules (neuroligin, neurexin)
- Mechanism: Enhance synaptic formation and stability
Synaptic plasticity involves a balance between strengthening (LTP) and weakening (LTD) processes. In PD, this balance is disrupted.
Phosphatase Inhibitors
- Target: Protein phosphatases (calcineurin, PP1)
- Mechanism: Shift balance toward LTP
- Status: Preclinical research
Kinase Activators
- Target: CaMKII, PKA, PKC pathways
- Mechanism: Enhance LTP induction mechanisms
- Example: Bryostatin (PKC activator)
cAMP Modulators
- Target: cAMP/PKA signaling pathway
- Mechanism: Enhance second messenger signaling
- Example: Phosphodiesterase inhibitors
¶ Active and Recruiting Trials
| Trial ID |
Intervention |
Phase |
Mechanism |
Status |
| NCT05651464 |
Amantadine extended-release |
Phase II |
NMDA modulation |
Recruiting |
| NCT05532657 |
D-Serine (NBTX-001) |
Phase I |
NMDA co-agonist |
Completed |
| NCT05463731 |
Glutamate modulators |
Phase II |
AMPA modulation |
Active |
| NCT05508789 |
Synaptic plasticity enhancer |
Phase I |
Multi-target |
Recruiting |
CX516 (Ampakine) Studies
- Phase II for PD cognition
- Results: Modest improvement in cognitive measures
- Challenge: Short half-life limiting efficacy
D-Cycloserine Studies
- NMDA receptor partial agonist
- Mixed results in PD studies
- Ongoing optimization of dosing
Amantadine Studies
- NMDA receptor antagonist with plasticity effects
- Shown to improve dyskinesias
- Mechanism may involve plasticity normalization
¶ Therapeutic Candidates and Pipeline
| Compound |
Company |
Mechanism |
Phase |
Indication |
| Amantadine ER |
Adamas |
NMDA modulation |
Phase III |
PD dyskinesia |
| D-serine |
多家 |
NMDA co-agonist |
Phase II |
PD dementia |
| CX516 |
Cortex |
AMPA PAM |
Phase II |
PD cognition |
¶ Preclinical Candidates
Novel NMDA Modulators
- GluN2B-selective compounds
- Allosteric modulators with improved side effect profiles
AMPA Receptor Enhancers
- Optimized Ampakine derivatives
- Positive allosteric modulators with better brain penetration
Dendritic Spine Protectors
- Actin polymerization modulators
- Rho kinase inhibitors
Multi-target Approaches
- Combined dopamine and plasticity enhancement
- Disease-modifying small molecules
- With Levodopa: Enhance plasticity without increasing dyskinesias
- With Dopamine Agonists: Synergistic effects on circuit function
- With MAO-B Inhibitors: Neuroprotection plus plasticity enhancement
- With GLP-1 Receptor Agonists: Complementary neuroprotective pathways
- With Deep Brain Stimulation: Modulate plasticity to enhance DBS effects
- With Physical Rehabilitation: Activity-dependent plasticity enhancement
¶ Challenges and Considerations
Many plasticity-targeting compounds face challenges reaching the brain:
- Molecular weight and polarity requirements
- Active transport mechanisms
- Efflux transporter considerations
Targeting synaptic plasticity without disrupting normal function:
- Dose-dependent effects on neural circuits
- Region-specific targeting (striatum vs. cortex)
- Temporal specificity (acute vs. chronic treatment)
Measuring synaptic plasticity in clinical trials:
- PET ligands for synaptic density (SV2A)
- CSF synaptic biomarkers (neurogranin, SNAP-25)
- Electrophysiological measures (TMS)
- Behavioral readouts
Challenges in translating findings:
-rodent to human differences
- Age-related plasticity changes
- Chronic vs. acute disease modeling
- Delivery of plasticity-enhancing genes
- Viral vectors targeting specific neuronal populations
- CRISPR-based modifications
- Stem cell-derived neurons with enhanced plasticity
- Gene-modified cells secreting neurotrophic factors
- Organoid-based approaches
Combining with:
- Deep brain stimulation
- Transcranial magnetic stimulation
- Transcranial direct current stimulation
¶ Related Mechanisms and Pages